SCHEDULE: Novo Holdings Cuts IO Biotech Stake to 7.3%

Novo Holdings A/S has reduced its beneficial ownership in IO Biotech, Inc. to approximately 7.3% after selling 841,996 shares in a block trade.

Summary

• Novo Holdings A/S sold 841,996 shares of IO Biotech, Inc. Common Stock on August 11, 2025.
• The shares were sold at a price of $1.7673 per share in a block trade.
• Following the sale, Novo Holdings A/S beneficially owns 4,981,588 shares, comprising 2,512,453 common shares and 2,469,135 shares issuable from warrants.
• This represents approximately 7.3% of IO Biotech's outstanding Common Stock.
• The calculation is based on 65,880,914 shares outstanding as of August 11, 2025, as reported in IO Biotech's Form 10-Q filed on August 14, 2025, plus the warrant shares.

Sentiment

Score: 3

Explanation: The reduction of a significant stake by a major institutional investor like Novo Holdings A/S is generally viewed negatively by the market, as it can signal a lack of confidence or a strategic shift away from the company. This could lead to downward pressure on the stock price.

Negatives

• A significant investor, Novo Holdings A/S, has reduced its stake in IO Biotech, Inc. by selling 841,996 shares.
• This reduction in ownership from a major institutional holder could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic reallocation of capital away from the issuer.

Risks

• The reduction in ownership by a significant institutional investor like Novo Holdings A/S could lead to decreased investor confidence and potential downward pressure on the stock price.
• The sale of a large block of shares could increase market volatility for IO Biotech's stock.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the issuer's future operations or financial performance.

Industry Context

This filing primarily details a change in a significant investor's stake in IO Biotech, Inc. and does not provide broader industry context or trends. It reflects a specific investment decision by Novo Holdings A/S within the biotechnology sector.

Stakeholder Impact

• Shareholders: The reduction in stake by a major investor could lead to negative market sentiment and potential downward pressure on the share price.
• Investors: May interpret the sale as a signal to re-evaluate their positions in IO Biotech.

Key Dates

Recommendation

While a major investor reducing their stake is a negative signal, the filing itself does not provide enough information about IO Biotech's underlying business, financials, or future prospects to warrant a 'sell' recommendation. It suggests caution and a 'hold' stance, prompting investors to investigate the reasons behind Novo Holdings' divestment and assess the company's fundamentals independently.

Keywords

IO Biotech, Novo Holdings, Schedule 13D, Stake Reduction, Common Stock, Biotechnology, Institutional Investor, Share Sale, SEC Filing